The HER2 (ERBB2) and MYC genes are commonly amplified in breast cancer, yet little is known about their molecular and clinical interaction. Using a novel chimeric mammary transgenic approach and in vitro models, we demonstrate markedly increased selfrenewal and tumour-propagating capability of cells transformed with Her2 and c-Myc. Coexpression of both oncoproteins in cultured cells led to the activation of a c-Myc transcriptional signature and acquisition of a self-renewing phenotype independent of an epithelial-mesenchymal transition programme or regulation of conventional cancer stem cell markers. Instead, Her2 and c-Myc cooperated to induce the expression of lipoprotein lipase, which was required for proliferation and self-renewal in vitro. HER2 and MYC were frequently coamplified in breast cancer, associated with aggressive clinical behaviour and poor outcome. Lastly, we show that in HER2 þ breast cancer patients receiving adjuvant chemotherapy (but not targeted anti-Her2 therapy), MYC amplification is associated with a poor outcome. These findings demonstrate the importance of molecular and cellular context in oncogenic transformation and acquisition of a malignant stem-like phenotype and have diagnostic and therapeutic consequences for the clinical management of HER2 þ breast cancer.
INTRODUCTION
Despite dramatic advances in the clinical management of breast cancer over the past 20 years, treatment of breast cancer remains a major clinical challenge worldwide, with more than 400 000 women estimated to die from breast cancer each year. 1, 2 Approximately 15-20% of breast cancers have amplification of HER2 (HER2 þ ), with up to 25-50 copies of the gene per cell that is associated with a relatively poor prognosis. [3] [4] [5] c-Myc is a member of the basic helix-loop-helix transcription factor family and is amplified in many malignancies including in B12-18% of breast cancers. [6] [7] [8] [9] [10] Intriguingly, several studies have reported that many MYC-amplified breast cancers also harbour HER2 amplification, suggesting a selection for coamplification. 11, 12 c-Myc cooperates in transformation with the activation of a variety of kinase signalling pathways and was identified as a downstream target of Her2-phosphatidylinositol 3-kinase signalling more than a decade ago. 13 Yet, despite being two of the most commonly amplified genes in breast cancer, little is known about the interaction of Her2 and c-Myc in breast cancer aetiology or the impact of MYC amplification on the HER2 þ cancer phenotype. [13] [14] [15] In this work, we demonstrate a potent interaction between Her2 and c-Myc, which drives mammary oncogenesis. Using mouse models and in vitro assays, we demonstrate that transformation with Her2 and c-Myc is sufficient to impart high self-renewal and tumourpropagating capacity. Transcriptomic analysis revealed that Her2 potentiates the expression of Myc target genes, specifically lipoprotein lipase (LPL), indicating the essential role for LPL in self-renewal in the context of cancer cell survival. Analysis of a clinical cohort validated that coamplification of HER2 and MYC is common in breast cancer and associates with poor prognosis. Importantly, we also find that MYC amplification correlates with poor prognosis in HER2 þ patients receiving adjuvant chemotherapy. Thus, our studies reveal a role for Her2 and c-Myc cooperation in the development of aggressive tumours with high self-renewal and tumour-propagating characteristics.
RESULTS

Generation of mouse tumour models to study the interaction of Her2 and c-Myc
To experimentally test the interaction of Her2 and c-Myc activation in vivo, we used a chimeric mouse transgenic method, which has been successfully used previously to generate mammary-specific transgenics 15 ( Figure 1A ). The expression of the relevant oncogenes was confirmed by immunoblotting of extracts taken from transfected mammary epithelial cells (MECs) Figure 1D ) before transplantation and from tumours that developed subsequently.
Only 1 of 10 c-Myc (M) transgenic mice developed a tumour, with a latency of 200 days. [15] [16] [17] The expression of a truncated constitutively activated form of Neu (N), 18 the rodent homolog of Her2, alone generated tumours in 10 of 17 mice with a median tumour-free survival of 178 days, almost identical to the mouse mammary tumour virus-Neu transgenic mouse. 19 In contrast, c-Myc cooperated with Neu in tumourigenesis (NM), driving the early development of tumours with median tumour-free survival of 102 days and 100% penetrance ( Figure 1B ). Gene expression profiling for classification 20, 21 revealed that the NM tumours clustered with the claudin-low subtype and were enriched in the expression of mesenchymal genes ( Figure 1C (b, e) ). Detailed characterization of the tumour models included array comparative genomic hybridization (CGH) analysis to determine copy number variants ( Figure 1D ). The NM tumours were more genomically unstable than N tumours, with a greater number of amplifications/deletions or rearrangements across multiple loci (Supplementary Table T6 ). One of the NM tumours (5037) had high amplification of MYC, which was reflected in high expression of c-Myc (Supplementary Figure 1D) . Interestingly, the other NM tumour (5038) did not show any c-Myc amplification, but had high expression of Myc and Neu. Histopathological examination of tumours revealed that the retroviral Neu model developed luminal cytokeratin-positive (CK 8) adenocarcinomas, closely resembling those described in the mouse mammary tumour virus-Neu transgenic models 22 (Supplementary Figure 1C) . The expression of c-Myc alone caused increased branching and hyperplastic lateral budding in all cases (data not shown), as previously described in transgenic and chimeric mouse models. [15] [16] [17] NM tumours were well defined and circumscribed with central necrosis and expressed the basal/ myoepithelial markers cytokeratins 6 and 14.
Self-renewal capacity of NM tumours is greatly enhanced compared with those transformed by Neu alone There is accumulating evidence that acquisition of a stem-like state is associated with a poor-prognosis phenotype in cancer. 23, 24 c-Myc 7 and Her2 5 have both been implicated in the generation or maintenance of mammary stem and progenitor cells. We therefore asked whether NM tumours were enriched for selfrenewal using serial passage in the 'tumoursphere' assay as shown in the schematic (Supplementary Figure 1A) . In this assay, primary tumoursphere-forming capacity is indicative of short-term proliferative capacity, whereas sphere-forming capacity upon passage is proportional to self-renewal capacity. Although there was no difference between groups in primary sphere-forming capacity, NM tumour cells had an approximately eightfold enrichment in tumoursphere formation over those derived from N tumours after serial passage (Figures 2a and b) . Interestingly, MECs transformed by Neu alone were not enriched for self-renewal when compared with control MECs. c-Myc alone generated tumours too rarely to Figure 1A) . All single tumourspheres rapidly generated palpable tumours in vivo, demonstrating extensive self-renewal and tumour-propagating capacity of even a single NM tumour cell. We further confirmed the tumour-propagating frequency (TPF) of cells taken from each model using limiting dilution transplantation of tumour cells into syngeneic mice (Supplementary Figure 1B) . N tumours cells contained rare tumour-propagating cells at an average frequency of B1 in 3907 cells, very similar to that reported previously in the mouse mammary tumour virusNeu model (Figure 2c) . 25, 26 In stark contrast, the TPF of the NM tumour cells across all tumours was 1 in 212. In one clone, o10 cells were required for tumour propagation. Therefore, coexpression of Neu and c-Myc drives the rapid development of tumours with massive self-renewal potential and 20-fold enrichment in TPF compared with Neu on its own.
To determine the potency of these cells to differentiate and proliferate, we analysed the cytokeratin and proliferative staining pattern of tumours generated by the lowest cell dilution ( Figure 2d and Supplementary Table T1 ). We did not observe any significant difference in the proliferative index (as determined by phosphohistone H3). This suggests that the aggressive phenotype observed by the cooperation of Her2 and c-Myc is not mainly driven by proliferation. Table T1 ).
All cultures formed equivalent numbers of tumourspheres at the first passage (Supplementary Figure 2B) ; however, upon passage, HM cells formed a significantly higher number of tumourspheres when compared with control cells or those expressing either oncogene alone (Figure 3b ). Thus, activation of c-Myc and Her2 is sufficient to impart increased self-renewal.
Her2 and c-Myc cooperation does not correlate with an EMT programme or the expression of CSC markers To understand the molecular changes underpinning the acquisition of this CSC phenotype, we evaluated the effects of Her2 and c-Myc on known Her2 effector pathways and did not observe any significant changes in the phosphorylated forms of the Ras/ mitogen-activated protein kinase or phosphatidylinositol 3-kinase/ AKT pathway between the modified cell lines (data not shown).
13,14 c-Myc activity is regulated by phosphorylation on Thr58 and Ser62 by a number of kinases including GSK-3b 27 and Erk, 28 but there was a comparable increase in the p-c-MycT58 and p-c-MycS62 forms in both M-and HM-modified cell lines (Supplementary Figure 2C) .
Previous data implicate the activation of an EMT programme by Her2 overexpression in the acquisition of a CSC-like phenotype 29 and we observed an increase in the TPF of NM tumours ( Figure 2c ). Consistent with previous reports, H cells had decreased levels of E-cadherin (an epithelial marker) and increased expression of vimentin (mesenchymal marker), whereas overexpression of c-Myc had the converse effect (Figure 3c ). However, HM cells expressed both vimentin and E-cadherin at levels similar to those observed in control cells. This was supported by the expression of miR-200c, which is known to have a critical role in suppressing EMT 30, 31 (Supplementary Figure 2D) . In addition, we verified these observations by gene set enrichment analysis (GSEA) (as described in Materials and methods section) and demonstrate that two gene sets representative of EMT 32, 33 (SARRIO_EPITHELIAL_MESENCHYMAL_ TRANSITION_UP, ALONSO_METASTASIS_EMT_UP) (Supplementary Figure 2E) are both elevated in H cells, reduced in M cells and at levels similar to control in HM cells. Thus, it appears that Her2 and c-Myc cooperate to drive the acquisition of a self-renewing CSC phenotype through mechanisms distinct from the EMT programme.
We analysed the expression of a panel of commonly used CSC markers 34, 35 in our cell line models. 36, 37 We observed an approximately threefold increase in the CSC fraction in H compared with control cells (Figure 3d ) as reported previously. 5 Myc overexpression led to an approximately sixfold increase in this cellular fraction, which was very similar to that seen in cultures overexpressing both oncogenes. When compared with the results of tumoursphere assays shown in Figure 3b , these data suggest that the CSC markers do not necessarily mark cells with greater self-renewal capacity. Similarly, expression of the murine CSC markers, CD29, CD24 and CD61, 38 did not correlate with selfrenewal or TPF when we examined N and NM mouse tumours using flow cytometry (data not shown).
Transcriptional analysis of Her2 and c-Myc cooperation
We used transcriptomic analysis to explore the possibility that alterations in the c-Myc-dependent transcription programme underlie the cooperation between Her2 and c-Myc. We performed whole genome expression profiling to define data sets for MCF10A cells expressing H, M, HM or V. Limma analysis revealed unique and partially overlapping patterns of expression in each group, including eight genes that were uniquely upregulated and 18 downregulated in the HM signature (Supplementary Figure 3A) . Genes of interest were selected for validation by quantitative realtime polymerase chain reaction (qRT-PCR) based on their unique expression in the HM data set and their potential functional role in breast cancer. There was more than a 14-fold increase in LPL levels compared with vector control (Figure 4a ) in the HM group.
We used GSEA 39 to understand the functional and regulatory relationships between genes in the H, M and HM signatures. We systematically looked for gene sets that were enriched in the HM 39 ) that were enriched in the HM signature when compared with the H or M signatures. We investigated the curated 'C2' gene sets, leading to the identification of 40 enriched gene sets (Figure 4b ) encompassing a diversity of processes including a number of signatures associated with poor prognosis cancers.
Of interest, several gene sets involved in sterol and lipid biology (REACTOME_CHOLESTEROL_BIOSYNTHESIS and REACTOME_STER-OID_METABOLISM) were significantly upregulated in the HM group (Figure 4b) . 40 We also found a significant correlation between the HM gene signature and a poor prognosis gene expression signature previously associated with high expression of LPL, a gene involved in lipid utilization and cholesterol uptake. A set of genes (BILBAN_B_CLL_LPL-DN; Bilban et al. 41 ) with reduced expression in tumours with high LPL (patients with poor prognosis) were also downregulated in the HM group (Figure 4b ). To test whether LPL was important to the phenotype of these cells, we tested the impact of LPL depletion on proliferation and self-renewal. Surprisingly, depletion of LPL in all four cell lines led to a significant decrease in proliferation and tumoursphere formation (Figure 4c,d) . Although cell lines transduced with control short hairpin RNA formed about five primary tumourspheres per 1000 cells, LPL knockdown led to a complete abrogation in tumoursphere formation of all the cell lines (Figure 4d ), suggesting an important role for LPL in selfrenewal or survival in suspension culture.
GSEA analysis also showed that genes that were significantly downregulated in MYCN-amplified cancer cells (KIM_MYC-N_AMPLIFICATION_TARGETS_DN) 42 were also significantly downregulated in the M and HM cells (Figure 4b and Supplementary Figure 3B) . However, Her2 and c-Myc (q-value of 0.0001) cooperated to downregulate the MYCN targets much more significantly than c-Myc (q-value of 0.01) overexpression alone, showing a 30% decrease in the GSEA NES for the HM cells. In addition, using the 'C3' transcription factor motif gene sets in GSEA, a significant upregulation (qo0.05) of genes enriched with MYC binding sites was seen for the HMcoexpressing cells but not in either of the H or M. These data suggest that coexpression with Her2 amplifies the expression of a set of Myc transcriptional targets. (Figure 5a ), followed by survival analysis (Figure 5b ). There were 272 cases for which HER2 and MYC FISH was interpretable (Tables 1 and 2 ). Of these, 12.1% and 16.79% of cancers were HER2 and MYC amplified, respectively. However, 29.2% of MYC amplifications occurred in the context of HER2 amplification, suggesting selection for coamplification of HER2 and MYC. We validated these findings using data from The Cancer Genome Atlas, which contains 821 breast cancer samples with available amplification status of both HER2 and MYC, assessed by single-nucleotide polymorphism ChIP analysis (Supplementary Figure 3D) . 43 Using the cBio data portal, 44 we determined that 12.4% (102/821) had HER2 amplification and 13.5% (111/821) had MYC amplification. Further, of the HER2-amplified breast cancers, 19.6% (20/102) had MYC amplification, which corroborates our findings from the CREA cohort ( Figure 5d ). As expected from the (Figure 5b ). Coamplification of HER2 and MYC was also associated with larger tumours, histological grade 3 and high Ki-67 expression. One of the phenotypes associated with CSCs is their inherent resistance to cytotoxic chemotherapy, which also contributes to relapse. 45, 46 We analysed the outcome of a subgroup of patients who received adjuvant chemotherapy and found that patients with coamplification of HER2 and MYC had a very poor outcome (Figure 5c ). Using univariate analysis, coamplification of HER2 and MYC was associated with an HR of 9.3 (95% CI: 2.04-42.3; P ¼ 0.004) compared with amplification of MYC (HR, 3.8; 95% CI: 1.3-11.7; P ¼ 0.02) or HER2 (not significant). There have been conflicting reports on the association between MYC amplification in the context of HER2 breast cancer patients and response to herceptin therapy. 47 We treated the Her2-and c-Myc-overexpressing cell lines with herceptin and assessed their self-renewal potential (Supplementary Figure 2F) . The secondary tumoursphere-forming capacity of HM cells was robustly inhibited by herceptin treatment, suggesting that HER2 patients with MYC amplification may still benefit from herceptin treatment.
Coamplification of
HER2 and MYC correlates with poor prognosis To determine whether HER2 and MYC amplification status predicted clinical behaviour, we performed fluorescence in situ hybridization (FISH) for HER2 and MYC on a cohort of 292 patients
DISCUSSION
Extensive heterogeneity exists at the inter-and intratumoral level in breast cancer. 48 There is increasing evidence that the tumourigenic and metastatic properties of some breast cancers are driven by subpopulations of cells (CSC) within the tumour with high self-renewal capacity. 36, 49, 50 We show here that cooperation of Her2 and c-Myc in malignancy promotes the formation of mammary tumours enriched with such cells. Earlier work 5 suggested that Her2 regulates the mammary stem/progenitor cell population, driving tumourigenesis and invasion. In addition, c-Myc has also been implicated in the generation or maintenance of physiological mammary stem cells and progenitor cells. 7 However, we have shown very modest effects of either oncogene alone on the tumour-propagating capacity and selfrenewing phenotype compared with the large impact of coexpression of both oncogenes. Gene expression profiling for classification 20, 21 revealed that the NM tumours clustered with claudin-low or basal-like mouse tumours and were enriched in the expression of mesenchymal genes ( Figure 1C (b, e) ). Several studies have alluded to the heterogeneous biology of HER2-overexpressing breast cancers. 51, 52 The NM tumours (Supplementary Figure 1C) resemble the basal-HER2 þ breast cancers (oestrogen receptor-negative, HER2-positive and basal cytokeratin-positive), which constitute approximately 10% of HER2 þ breast cancers, and have poorer 5-year survival than basal-like breast cancers. The NM tumours generated might be a clinically relevant model in which we can test different treatment strategies in basal-HER2 breast cancers. In addition, array CGH analysis showed that NM tumours were more genomically unstable than N tumours, with a greater number of amplifications/deletions or rearrangements across multiple loci ( Figure 1D and Supplementary Table T6 ), which may be related to the previously described role for c-Myc in genomic instability. 53 Coexpression of Her2/Neu and c-Myc (NM) was sufficient to significantly decrease survival time of mice ( Figure 1B) , increase self-renewal in sphere-forming assays (Figure 2b ) and was associated with an average 20-fold increase of in vivo tumourpropagating capacity (Figure 2c) , with some spontaneous tumours composed entirely of tumour-propagating capacities.
Strikingly, the acquisition of this phenotype is independent of a canonical EMT programme, which has been suggested to be intimately linked to the acquisition of a CSC phenotype 54 Cooperation of Her2 and c-Myc in breast cancer R Nair et al (Figure 3c and Supplementary Figure 2D and E) . This corroborates recent work 55 that the acquisition of an EMT programme by cancer cells can, in fact, suppress human tumour-initiating capability. The existence of epithelial tumour cell subpopulations that reversibly acquire a mesenchymal-like invasive state has been demonstrated in other models like prostate cancer. 55 Interestingly, in our model, HM cells express intermediate levels of both the epithelial and mesenchymal markers (Figure 3c ). This observation was also supported by GSEA using representative EMT gene sets, suggesting that HM cells may transition between an epithelial and mesenchymal state.
In an effort to understand the molecular mechanisms by which Her2 and c-Myc cooperate, we used transcriptomics. Surprisingly, very few genes were dramatically regulated by coexpression of Her2 and c-Myc. One of these was LPL, an enzyme involved in triglyceride metabolism and cellular uptake, 56 which was strongly upregulated specifically in the HM cells. LPL has recently been reported as overexpressed in breast cancer 57 and subject to genomic translocations in squamous cell carcinoma. 58 GSEA analysis revealed global similarities between the transcriptome of HM cells and poor-prognosis B-CLL cells expressing high levels of LPL. 41, 59 B-CLL is commonly associated with c-Myc overexpression, 60 and analysis of ENCODE 61 ChIP-Seq data revealed that c-Myc can bind to regions proximal to the LPL promoter in MCF10A cells, demonstrating the possibility of direct regulation by c-Myc (Supplementary Figure 3E) . Knockdown of LPL in all the cell lines had a dramatic effect on the proliferative and tumoursphere-forming ability of cells, implying that LPL is important for their survival or self-renewal (Figure 4c,d) . Interestingly, LPL is known to have a role in cholesterol metabolism and two gene sets involved in cholesterol biosynthesis and steroid metabolism were also significantly upregulated in the HM group (Figure 4b) . LPL drives triglyceride hydrolysis in addition to fatty acid and lipoprotein uptake, which may act to create a fuel-rich niche for cancer cells. 62, 63 On a broader scale, we observe a global quantitative increase in Myc-dependent transcription, rather than the acquisition of a novel repertoire of genes expressed. Whether these quantitative increases in the expression of many c-Myc targets contribute to the acquisition of a stem-like phenotype is unknown. However, we suggest that the function of c-Myc in cancer is dependent on the oncogenic milieu in which it is expressed (e.g., in the presence of HER2 amplification) and that the function of c-Myc depends on certain thresholds of transcriptional activity. The importance of thresholds to Myc activity in cancer has previously been implicated in the induction of apoptosis by c-Myc. 64, 65 Our work suggests that thresholds may similarly control other aspects of c-Myc function and resembles previous reports that embryonic stem cell self-renewal is associated with increased expression of many hundreds of Myc target genes. 23 Our data demonstrate that only in the context of Her2 activation did c-Myc drive the acquisition of an aggressive stemlike phenotype, both in vivo (Figures 1 and 2 ) and in vitro (Figure 3 ). This may also help to explain why coamplification of MYC and HER2 is overrepresented in breast cancers and portends very poor prognosis compared with the amplification of either oncogene alone ( Figure 5 ). This may have important implications for the clinical management of HER2 þ patients. Further work is needed to determine whether MYC status defines HER2 þ breast cancers with fundamentally different biology or predicts response to cytotoxic chemotherapy or molecular targeted therapeutics such as herceptin and lapatinib.
MATERIALS AND METHODS
Preparation of primary MECs
Primary MECs from 8-to 12-week-old FVB/N recipient mice were cultured and retrovirally transduced as described previously 15, 66 and allowed to attach overnight. MECs were retrovirally transduced with Neu14-pMIL and c-Myc (hs) pMig 15 transplanted into the cleared mammary fat pad of recipients.
Microarray experiments and mouse intrinsic gene set analysis
Microarrays of new samples were performed as previously described using custom Agilent 180K mouse microarrays (Agilent Technologies Inc., Santa Clara, CA, USA). 67 These arrays were normalized to samples from GSE3165 (22K), GSE27101 (44K) and GSE35722 (180K) using previously published methods. 67 Specifically, five C3-Tag and five mouse mammary tumour virus-Neu tumours from each of the three platforms (30 microarrays total) were used to calculate a median normalization factor for common probes across all three platforms. Supervised clustering was performed using the 2007 intrinsic probe list. 20 Of the 866 original probes, 655 were found on all three array platforms used.
Copy number variation analysis by array CGH DNA was extracted from snap frozen mammary tumour and liver (reference from sex-matched wild-type FVB/N mouse) using the QIAamp DNA Mini Kit (Qiagen, Doncaster, VIC, Australia) according to the manufacturer's instructions. Array CGH was performed by the Ramaciotti Centre for Gene Function Analysis (Randwick, Sydney, NSW, Australia) on differentially labelled tumour DNA (Cy5) and sex-matched reference liver DNA (Cy3) using the Agilent SurePrint G3 mouse CGH 4 Â 180K microarray platform. The array CGH data were analysed using circular binary segmentation 68 to translate intensity measurements into regions of equal copy number. Analysis was carried out using the DNAcopy package (http: //www.bioconductor.org/) in R2.15.2 (http: //www.r-project.org/).
Preparation of tumours
Tumour cells were prepared as described before 69 and resuspended in the MEC medium.
Tumoursphere assay Dissociated cells from tumours or modified MCF10A cell lines were put into the tumoursphere assay as described previously. 36 Herceptin was added at a concentration of 21 mg/ml to assay for the effect of herceptin on selfrenewal.
Flow cytometry
Tumours were processed into single-cell suspensions before staining and fluorescence-activated cell sorting (FACS) as described previously 69 ( Table 3) . Flow cytometry was performed on a BD LSRII SORP using the FACS DIVA software (BD Biosciences, San Jose, CA, USA), and data were analysed using the FlowJo software (Treestar, Ashland, OR, USA).
Immunohistochemistry
Full details of the protocols for immunohistochemistry are shown in Supplementary Table T2 . Intrinsic breast cancer subtypes were assessed immunohistochemically using criteria similar to those recently described by Cheang and co-workers, 70 but using FISH to determine HER2 status. The details of antibodies, immunohistochemistry, in situ hybridization and scoring for these markers have been previously reported in the invasive ductal carcinoma cohort. 69 Limiting dilution assay Single-cell suspensions of viable tumour cells were prepared as described before in the Materials and methods section. Tumour cells were transplanted in appropriate numbers into the fourth mammary fat pad of 8-to 12-week-old syngeneic mice and aged till ethical end point. Extreme limiting dilution analysis 71 software was used to calculate the TPF. 0 -CCGGGCTCTGCTTGAGTTGTAGAAACTCGAGT TTCTACAACTCAAGCAGAGCTTTTTG-3 0 and appropriate controls were used to generate V, H, M and HM cell lines with LPL knockdown. Live cultures were analysed using time-lapse phase-contrast microscopy at 37 1C with the automated Live Cell Imaging System IncuCyte zoom40061 FLR (Essen Bioscience Inc., Ann Arbor, MI, USA). A total of 2 Â 10 4 cells per well were seeded triplicate in a 24-well plate, which was immediately loaded into the IncuCyte imaging system. Nine images per well were collected at 2 h intervals. The percent confluence of the live cultures was calculated using the IncuCyte software (Essen Bioscience Inc.). Briefly, average confluence was calculated using individual data from each of the nine images taken per well at each time point. The data points represent the mean of three wells ( ± s.e.m.). Data analysis was completed using Prism (GraphPad Software, La Jolla, CA, USA).
MTS assay
Cell viability assay (MTS assay) was carried out using the CellTiter 96 AQueous Cell Proliferation Assay (G5421; Promega, Alexandria, NSW, Australia) according to the manufacturer's recommendation.
Western blots
Protein lysates were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels following transfer to 0.45 mm polyvinylidene difluoride membranes as described previously using standard procedures. 66 The membranes were incubated with primary antibody solutions at concentration according to Supplementary Table T3. Quantitative real-time PCR cDNA was generated from 500 ng of RNA using the Superscript III firststrand synthesis system (Invitrogen, Mulgrave, VIC, Australia) according to the manufacturer's protocol. Quantitative real-time PCR was carried out using the Roche Universal ProbeLibrary System (Roche Diagnostics, Castle Hill, NSW, Australia) on the Roche LightCycler480 (see Supplementary  Table T5) as per the manufacturer's instructions, using primers as shown in Supplementary Table T4 .
Transcript profiling
Total RNA was extracted by using the Qiagen RNeasy minikit (Qiagen, Doncaster, VIC, Australia) according to the manufacturer's protocol. mRNA expression profiling was performed by the Ramaciotti Centre for Gene Function Analysis (Kensington, NSW, Australia) using the Affymetrix GeneChip Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA). Because of one of our Myc-overexpressing samples failing quality control, we removed this from the microarray analysis. Normalization and probe set summarization was performed using the robust multichip average 73 implemented in the Affy library 74 from R. 75 Control probe sets were removed leaving 28 869 probe sets on the array. Differential gene expression was then assessed for each probe set using an empirical Bayes, moderated t-statistic implemented in Limma 76 using the limmaGP tool in GenePattern. GSEA 39 was run with the GenePattern tool GSEApreranked using a ranked list of the Limma moderated t-statistics against version 3.0 of the 'C2_all' curated gene sets from the MSigDB. 39 All analyses were performed using GenePattern software 77 and are available at http://pwbc.garvan.unsw.edu.au/gp/. Microarray data are available from GEO: GSE43730.
Patients
The Garvan/St Vincent's Hospital outcome series comprises 292 operable invasive ductal carcinomas of the breast from patients treated by a single surgeon between February 1992 and August 2002 at St Vincent's Hospital, Sydney, NSW, Australia. Ethics approval was granted for the use of pathology specimens and cognate clinicopathological data (Human Research Ethics Committee of St Vincent's Hospital, Sydney, NSW, Australia). A more detailed description of the clinicopathological characteristics of the cohort is published elsewhere. [78] [79] [80] Fluorescence in situ hybridization HER2 FISH was performed by Dr Adrienne Morey and co-workers 81 in the HER2 FISH Reference Lab at St Vincent's Hospital, according to routine protocols used for diagnostic cases. HER2 gene amplification was defined as a HER2/chr17 ratio 42.2. MYC ISH was performed using similar methods, but using the Vysis MYC/CEP8 probe. A minimum of 20 cells for each tumour was counted by a specialist breast pathologist (SO'T). A mean score for MYC, CEP8 and the MYC/CEP8 ratio was calculated. Using the criteria of Perez et al., 82 an MYC/CEP8 ratio of 41.3 or a mean tumour cell MYC copy number of 45 was used to determine cases with MYC amplification.
Statistical analysis
Statistical evaluation was performed using Statview 5.0 Software (Abacus Systems, Berkeley, CA, USA). A P-value of o0.05 was accepted as statistically significant. Cooperation of Her2 and c-Myc in breast cancer R Nair et al
